1 active not recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
Follow Refractory Ependymoma: new trials by email Literature Review of Refractory Ependymoma trials Research Report on Refractory Ependymoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging - Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 71 | 2015-06-03 | 2026-07-20 |
Brain Neoplasms (1) · Colorectal Neoplasms, Hereditary Nonpolyposis (1) · Diffuse Intrinsic Pontine Glioma (1) · Ependymoma (1) · Familial ependymoma (1) · Glioma (1) · Medulloblastoma (1) · Turcot syndrome (1)
Brain Diseases (1) · Brain Stem Neoplasms (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Colonic Diseases (1) · Colorectal Neoplasms (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · DNA Repair-Deficiency Disorders (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Genetic Diseases, Inborn (1) · Infratentorial Neoplasms (1) · Intestinal Diseases (1)
Diffusion Tensor Imaging (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · pembrolizumab (1)
National Cancer Institute (NCI) (1)
Canada (1) · United States (1)
Eugene I Hwang (1)
UM1CA081457 (1)